Transgene News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.07.17	Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus (Businesswire)
05.07.17	Half-Year Report on the Transgene Liquidity Contract with Kepler Cheuvreux (Businesswire)
05.01.17	Half-Year Report on the Transgene Liquidity Contract with Kepler Cheuvreux (Businesswire)
07.12.16	Transgene: UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) (Businesswire)
14.11.16	Transgene Presents Preclinical Results of TG1050, an HBV-targeted Immunotherapy, at AASLD 2016 Liver Meeting (Businesswire)
10.11.16	Successful Completion of Transgene’s Rights Issue (Businesswire)
20.10.16	Transgene Reports Third Quarter 2016 Financial Results (Businesswire)
17.10.16	First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients (Businesswire)
11.10.16	Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study (Businesswire)
11.10.16	Transgene Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study (Businesswire)
05.10.16	Transgene Presents Data on Improved Cytotoxic Activity of Oncolytic Viruses Expressing Intrabodies in Resistant Tumor Cell Lines (Businesswire)
05.09.16	Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials (Businesswire)
01.09.16	Transgene Announces Participation at Upcoming Investor Events (Businesswire)
21.07.16	Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee (Businesswire)
31.05.16	Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy (Businesswire)
25.05.16	Transgene : Composition of the Board of Directors and Statutory Auditors (Businesswire)
21.04.16	Transgene Reports First Quarter 2016 Business Update (Businesswire)
19.04.16	Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody (Businesswire)
17.03.16	Transgene Hires Two Senior Pharmaceutical Industry Executives to Join Leadership Team (Businesswire)
08.03.16	Transgene Reports 2015 Financial Results and Provides Outlook for 2016 (Businesswire)
02.03.16	Transgene Announces Participation at Upcoming Investor Events (Businesswire)
03.02.16	Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset (Businesswire)
28.01.16	EIB Lends EUR 20m to Transgene (Businesswire)
08.01.16	Transgene Announces Financial Calendar for 2016 (Businesswire)
07.01.16	Transgene Enters New Phase in Its Strategic Development (Businesswire)
06.01.16	Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer (Businesswire)
23.12.15	Transgene Announces Publication in "The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (Businesswire)
12.11.15	Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development (Businesswire)
04.11.15	Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection (Businesswire)
21.10.15	Transgene Reports Third Quarter 2015 Financial Results (Businesswire)
23.09.15	Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York (Businesswire)
10.09.15	Transgene Reports Financial Results for First Six Months of 2015 (Businesswire)
08.09.15	Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (Businesswire)
19.08.15	Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer (Businesswire)
29.06.15	Transgene Plans Restructuring to Focus on Research and Development (Businesswire)
01.06.15	Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (Businesswire)
18.05.15	Transgene Announces Participation at Upcoming Investor Events (Businesswire)
23.04.15	Transgene Presents New Data with TG1050, an Immunotherapy Being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015 (Businesswire)
22.04.15	Transgene Reports First Quarter 2015 Financial Results (Businesswire)
21.04.15	Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody (Businesswire)
16.04.15	Transgene SA: Agreement with FDA Announced for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer (Businesswire)
24.03.15	Transgene Reports 2014 Financial Results and Outlines Promising Clinical Pipeline (Businesswire)
19.03.15	Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR (Businesswire)
08.01.15	Transgene Announces Financial Calendar for 2015 (Businesswire)
29.10.14	Transgene Announces Events Calendar for Fourth Quarter 2014 (Businesswire)
21.10.14	Transgene Announces Third Quarter 2014 Financial Results (Businesswire)
09.10.14	Transgene Announces Management Changes (Businesswire)
29.09.14	Transgene Presents Additional Positive Clinical Data from Phase 2b Part of TIME Trial with TG4010 at ESMO (Businesswire)
23.09.14	Transgene Appoints Eric Quéméneur, PhD as Executive Vice President in Charge of Research & Development (Businesswire)
08.09.14	Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Transgene S.A.

Aktien Top/Flop

Meistgelesene Nachrichten